US$ 180 Million Revenue Emerging in Blood Cancer Diagnostics Market till 2022

Posted on 2019-03-29 by Mark Hub in Healthcare // 0 Comments

The purpose of this rich study presented by FactMR is to elaborate the various market projections impacting the global blood cancer diagnostics market during the period until 2022. This assessment delivers high-end statistics concerning market size (US$ 180 Mn), Y-o-Y growth and revenue share (US& Mn) linked to different geographies and segmentation types. Readers can acquire precise insights about growth trends along with opportunities that are expected to reshape the overall structure of the blood cancer diagnostics market during the forecast period. Blood cancer diagnostics can be defined as the wide range of screening & diagnosis tests associated with blood cancers such as lymphoma, leukemia and myeloma. Bone marrow examination, blood sample tests, complete blood count tests, flow cytometry, cupping therapy and genetic testing are prominent procedures in the diagnosis of blood cancer.

Request for Free Sample Report of Blood Cancer Diagnostics Market From Here – https://www.factmr.com/connectus/sample?flag=S&rep_id=47

Increase in the prevalence of oncological diseases and technological advancements in diagnostics are positively impacting the global blood cancer diagnostics market. Focus on detecting cancer at an early stage through molecular and RNA/DNA testing can widely improve the diagnosis. As spending on healthcare witnesses a gradual increase in developing countries, the overall blood cancer diagnostics market is projected to grow at a steady rate during the forecast period 2017-2022. According to FactMR’s analysis, the global blood cancer diagnostics market is projected to grow at a steady CAGR during the forecast period.

FactMR’s report offers market analysis and forecast on the global blood cancer diagnostics market on the basis of test type. Liquid biopsy is another test type that remains widely used among end-users. Studies have shown that liquid biopsy can overcome challenges related to intra- and inter-tumor heterogeneity. The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. Inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma. On account of growing preference for liquid biopsy, this segment is projected to increase at a CAGR of over 10% through 2022.

According to the report, the CBC test segment type of the global blood cancer market is valued at nearly US$ 77 million in 2017. By 2022, this is projected to grow at a healthy rate. The market in North America will remain lucrative for manufacturers throughout the forecast period. The CTC tests segment on the other hand, is anticipated to grow at a relatively higher CAGR than the CBC test segments.

Browse Blood Cancer Diagnostics Market Report with TOC Here – https://www.factmr.com/report/47/blood-cancer-diagnostics-market

Owing to accuracy and convenience of blood testing protein test type, it is anticipated that more end-use sectors will continue to use this type of testing globally. FactMR estimates the global blood protein testing market to rake in significant revenues during the forecast period. By end-users, hospital associated labs account for a significant percentage of the global blood cancer diagnostics market. Valued at over US$ 136 million in 2017, the hospital associated labs segment is projected to surpass US$ 180 million in revenues by 2022. Demand from hospital associated labs segment is projected to grow at a steady CAGR during the forecast period.

Demand for blood cancer diagnostics is also significant from the independent diagnostic laboratories segment. According to FactMR’s research, the independent diagnostics laboratories segment is projected to grow steadily through 2022. Cancer research institutes are also a key end-user, and demand from this segment is projected to grow at healthy CAGR through 2022. Overall, the global blood cancer diagnostics market is anticipated to witness steady growth through 2022. The market will continue to be influenced by regulatory policies and guidelines.

Competition Tracking

The key companies profiled in FactMR’s research include Abbott Laboratories, Roche Holding A.G., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc, NeoGenomics Laboratories, Inc., Siemens AG, Quest Diagnostics Incorporated, Qiagen N.V., Agilent Technologies, Biotheranostics, Inc, Almac Group Limited, and GeneNews Limited.

Do You Have Any Query or Specific Requirement? Ask Our Industry Expert – https://www.factmr.com/connectus/sample?flag=AE&rep_id=47

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick